Nunzia Pharmaceutical NUNZ · USD

Its shares trade under the ticker NUNZ. It has been listed since 23 January 1995.

Nunzia Pharmaceutical Corp. engages in the acquisition of other mines by purchasing and leasing of mineral right claims. The company is headquartered in Los Angeles, California. The firm focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The firm has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate. NUNZIA improves the lives of children and families suffering from ASDs and anxiety-based disorders. The firm is developing over the counter and pharmaceutical drug formulations of NUNZIA.

Figures and description from our data supplier, not checked against the company's own report.

• R. Steve MillsChairman of the Board, Chief Executive Officer, since 2005
• Kingman HitzChief Financial Officer, Vice President, since 2005
• Roger KronChief Operating Officer, Senior Vice President, Treasurer, Secretary, Director, since 2005
• G.David HenryDirector
• Mary PohlmeierDirector
• Robin SandiferDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.